Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

Jeux sans frontières

From regulations to customs, 2018 has some big questions to answer

Pharma and Brexit

Here at PMLiVE we began this year anticipating a year of change for pharma and, sure enough, we end the year knowing where the EMA is headed.

But, despite its impending Amsterdam move, 2017 has provided pharma with more questions than answers when it come to Brexit.

That’s particularly true if we try to guess the future shape of UK-EU pharma regulatory relations and the MHRA’s post-Brexit role.

The MHRA could only tell me it is working closely with the government. “We are clear, as is the government, on our desire to retain a close working partnership in respect of medicines regulation after the UK leaves the EU,” a spokesperson said.

“As part of the exit negotiations the UK will discuss with the EU and Member States how best to continue cooperation in the field of medicines regulation in the best interests of business, citizens and patients in both the UK and the EU.”

So, that’s clear then... perhaps.

At least the first phase of the negotiations will no longer hold up the vital next stage of the process.

But even when phase two kicks off in the new year, there are major questions to be faced about customs arrangements and trade deals, in addition to medicines regulations.

For now all that we can hope for is that these games with our frontiers will be played properly in 2018.

Article by
Dominic Tyer

Director of Editorial, PMGroup

22nd December 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics